Skip to content
DataLookout
Menu

NCT06111443

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

StatusActive, Not Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v2
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Freedom from all atrial tachyarrhythmias (AF/AFL/AT)
Timeframe: 3,6 and 12 months after ablation

Secondary (12)

Freedom from all atrial tachyarrhythmias (AF/AFL/AT) excluding the 3-month blanking period
Freedom from all atrial tachyarrhythmias (AF/AFL/AT) within 3-month blanking period
Total mortality or hospitalization due to CV cause
Left atrial (LA) size (LA dimension and LA volume index) by echocardiography
AF quality of life (QOL) by AF Effect On Quality-Of-Life (AFEQT) questionnaire score
Show 7 moreShow less
N-terminal pro-brain natriuretic peptide (NT-proBNP) level
Glycated Hemoglobin (HBA1c)
Creatinine (Cr) and estimated Glomerular filtration rate (eGFR)
Urine albumin/Cr ratio level
Repeated catheter ablation or cardioversion for atrial tachyarrhythmia
Adverse events: hypoglycemia, hypotension, hypokalemia, renal function deterioration
AF burden

Arms and interventions

DapagliflozinExperimental

Dapagliflozin (FORXIGA) 10 mg QD for 3 months

Usual careNo intervention

guideline-direct usual care

Drugs: Dapagliflozin 10 mg [Farxiga]

Sites

1 site in 1 country

  • Kaoshiung Chang Gung MemorialKaohsiung City, Taiwan